How to buy Lexaria Bioscience stock

Lexaria Bioscience, a Kelowna, Canada-based company that develops drug delivery platforms, is seeking a listing on the Nasdaq. The company is currently listed on the Over-the-Counter Markets under the ticker "LXRP," as well as the Canadian Securities Exchange under the ticker symbol "LXX."

Lexaria Bioscience share price

Use our graph to track the performance of LEXX stocks over time.

Lexaria Bioscience shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$4.11 - $12.90
50-day moving average	$5.55
200-day moving average	$5.69
Wall St. target price	N/A
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Lexaria Bioscience shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Lexaria Bioscience stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Lexaria Bioscience Corp by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lexaria Bioscience financials

Revenue TTM	$772,574
Gross profit TTM	$276,925
Return on assets TTM	-32.31%
Return on equity TTM	-35.13%
Profit margin	0%
Book value	N/A
Market capitalisation	$26.1 million

TTM: trailing 12 months

Shorting Lexaria Bioscience shares

There are currently 300,457 Lexaria Bioscience shares held short by investors – that's known as Lexaria Bioscience's "short interest". This figure is 2% up from 294,590 last month.

There are a few different ways that this level of interest in shorting Lexaria Bioscience shares can be evaluated.

Lexaria Bioscience's "short interest ratio" (SIR)

Lexaria Bioscience's "short interest ratio" (SIR) is the quantity of Lexaria Bioscience shares currently shorted divided by the average quantity of Lexaria Bioscience shares traded daily (recently around 70036.596736597). Lexaria Bioscience's SIR currently stands at 4.29. In other words for every 100,000 Lexaria Bioscience shares traded daily on the market, roughly 4290 shares are currently held short.

To gain some more context, you can compare Lexaria Bioscience's short interest ratio against those of similar companies.

• Pfizer (PFE.US): 2.26
• Moderna (MRNA.US): 1.39
• BioNTech (BNTX.US): 2.56

However Lexaria Bioscience's short interest can also be evaluated against the total number of Lexaria Bioscience shares, or, against the total number of tradable Lexaria Bioscience shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lexaria Bioscience's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Lexaria Bioscience shares in existence, roughly 60 shares are currently held short) or 0.0658% of the tradable shares (for every 100,000 tradable Lexaria Bioscience shares, roughly 66 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lexaria Bioscience.

Find out more about how you can short Lexaria Bioscience stock.

Lexaria Bioscience share dividends

We're not expecting Lexaria Bioscience to pay a dividend over the next 12 months.

You may also wish to consider:

• Pfizer (PFE.US) (3.9% forward annual dividend yield)

Lexaria Bioscience share price volatility

Over the last 12 months, Lexaria Bioscience's shares have ranged in value from as little as $4.11 up to $12.9. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lexaria Bioscience's is 1.7865. This would suggest that Lexaria Bioscience's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

To put Lexaria Bioscience's beta into context you can compare it against those of similar companies.

• Pfizer (PFE.US): 0.6733
• Moderna (MRNA.US): 1.4574

Lexaria Bioscience overview

Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada. .

Frequently asked questions

• What percentage of Lexaria Bioscience is owned by insiders or institutions?

  Currently 14.906% of Lexaria Bioscience shares are held by insiders and 0.119% by institutions.

• How many people work for Lexaria Bioscience?

  Latest data suggests 4 work at Lexaria Bioscience.

• When does the fiscal year end for Lexaria Bioscience?

  Lexaria Bioscience's fiscal year ends in August.

• Where is Lexaria Bioscience based?

  Lexaria Bioscience's address is: 100 ? 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7